In-hospital initiation of PCSK9 inhibitor and short-term lipid control in patients with acute myocardial infarction

BACKGROUND: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been shown to improve cardiovascular outcomes when added to conventional statin therapy. This study aims to investigate the efficacy and safety of in-hospital initiation of PCSK9 inhibitors among patients with acute my...

Descripción completa

Detalles Bibliográficos
Autores principales: Lou, Bowen, Liu, Hui, Luo, Yongbai, Jiang, Gulinigaer Tuerhong, Wu, Haoyu, Wang, Chen, Wu, Yue, Zhou, Bo, Yuan, Zuyi, She, Jianqing, Liu, Junhui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9590135/
https://www.ncbi.nlm.nih.gov/pubmed/36280861
http://dx.doi.org/10.1186/s12944-022-01724-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9590135/
https://www.ncbi.nlm.nih.gov/pubmed/36280861
http://dx.doi.org/10.1186/s12944-022-01724-9

Ejemplares similares